YHB Investment Advisors Inc. Boosts Holdings in Danaher Corporation $DHR

Key Points

• YHB Investment Advisors Inc. increased its position in Danaher Corporation shares by 3.7% in Q2, holding 84,726 shares valued at approximately $16.7 million.
• Danaher reported a quarterly earnings per share of $1.80, which exceeded analysts' estimates of $1.64, with a year-over-year revenue growth of 3.4%.
• The company has declared a quarterly dividend of $0.32 per share, translating to an annualized dividend of $1.28 and a yield of 0.7%.

YHB Investment Advisors Inc. raised its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 3.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,726 shares of the conglomerate's stock after buying an additional 2,999 shares during the period. Danaher comprises approximately 1.3% of YHB Investment Advisors Inc.'s investment portfolio, making the stock its 16th biggest position. YHB Investment Advisors Inc.'s holdings in Danaher were worth $16,737,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Ferguson Wellman Capital Management Inc. boosted its holdings in shares of Danaher by 49.7% in the second quarter. Ferguson Wellman Capital Management Inc. now owns 2,153 shares of the conglomerate's stock valued at $425,000 after purchasing an additional 715 shares during the period. Family Legacy Financial Solutions LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $5,217,000. NorthCrest Asset Manangement LLC boosted its holdings in shares of Danaher by 54.7% in the second quarter. NorthCrest Asset Manangement LLC now owns 1,978 shares of the conglomerate's stock valued at $402,000 after purchasing an additional 699 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Danaher by 1.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 210,828 shares of the conglomerate's stock valued at $42,840,000 after purchasing an additional 3,659 shares during the period. Finally, Tompkins Financial Corp boosted its holdings in shares of Danaher by 0.9% in the second quarter. Tompkins Financial Corp now owns 35,741 shares of the conglomerate's stock valued at $7,060,000 after purchasing an additional 335 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.20% of the stock is currently owned by insiders.

Danaher Stock Down 1.5%

Shares of DHR stock traded down $2.99 during trading hours on Monday, reaching $190.30. 2,949,617 shares of the company's stock were exchanged, compared to its average volume of 3,371,563. The stock's 50 day moving average is $200.02 and its 200-day moving average is $198.03. The company has a market cap of $136.26 billion, a price-to-earnings ratio of 40.49, a P/E/G ratio of 2.70 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the prior year, the firm posted $1.72 earnings per share. The business's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research reports. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a report on Friday, July 11th. Royal Bank Of Canada set a $241.00 target price on Danaher in a report on Tuesday, September 2nd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Deutsche Bank Aktiengesellschaft lowered their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, UBS Group lowered their target price on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.